 |
19 Diseases |  |
1 Trial |
|
1 Trial |  |
3312 News |  |
| «12345678910111213...4849» |
- | Invanz (ertapenem) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Epidemiological, clinical and microbiological characteristics of patients with biliary tract diseases with positive bile culture in a tertiary hospital. (Pubmed Central) - Sep 21, 2024
Linezolid and vancomycin were recommended for the treatment of Enterococci infections. Overall, this work can provide reference for clinical diagnosis, treatment and effective interventions.
- | Journal, Gram negative: National Survey and consensus document on dosing strategies for beta-lactam antibiotics against multidrug-resistant gram-negative bacilli (MDR-GNB) in critically ill patients undergoing extracorporeal life support techniques: The DOSEBL study protocol. (Pubmed Central) - Sep 20, 2024
The availability of extracorporeal life support techniques has expanded significantly in recent years, alongside a rise in the prevalence of infections caused by multidrug-resistant gram-negative bacilli (MDR-GNB). There is a need to develop evidence-based tools of high quality to standardize dosing and monitoring strategies for new ?-lactam antibiotics.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Evolution of ceftazidime-avibactam resistance driven by mutations in double-copy blaKPC-2 to blaKPC-189 during treatment of ST11 carbapenem-resistant Klebsiella pneumoniae. (Pubmed Central) - Sep 20, 2024
The multicopy forms of carbapenem resistance genes carried by the same plasmid are relatively rare in most carbapenem-resistant Enterobacteriaceae. In this study, we elucidate the evolutionary trajectory of CZA resistance in ST11 carbapenem-resistant K. pneumoniae harboring a double-copy blaKPC and provide new insights into the mechanisms of acquired resistance to CZA.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Maximally precise combinations to overcome metallo-?-lactamase-producing Klebsiella pneumoniae. (Pubmed Central) - Sep 20, 2024
Despite intrinsic mgrB and blaNDM-1 resistance, polymyxin B and ?-lactam combinations represent a promising strategy. Future studies using an integrated molecularly precise pharmacodynamic approach are warranted to unravel the mechanistic details to propose optimal antibiotic combinations to combat untreatable, pan-drug-resistant Gram-negatives.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Predicting Pseudomonas aeruginosa drug resistance using artificial intelligence and clinical MALDI-TOF mass spectra. (Pubmed Central) - Sep 18, 2024
In this study, we repurposed mass spectra generated by MALDI-TOF and used them as inputs for artificial intelligence approaches to successfully predict AMR in P. aeruginosa for multiple key antibiotic classes. This work represents an important advance toward using MALDI-TOF as a rapid AMR diagnostic for P. aeruginosa in clinical settings.
- || Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini
Clinical, Retrospective data, Review, Journal: Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. (Pubmed Central) - Sep 14, 2024
MV was associated with a similar risk of treatment discontinuation due to AEs (RR = 0.76, 95%CI [0.38, 1.49], p = 0.42) or drug-related AEs (RR = 0.56, 95%CI [0.28, 1.10], p = 0.09) as the comparators. In conclusion, MV presents a promising therapeutic option for treating CRE infections, demonstrating similar clinical and microbiological responses as other comparators, with potential advantages in mortality outcomes and renal-related AEs.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Artificial intelligence-clinical decision support system for enhanced infectious disease management: Accelerating ceftazidime-avibactam resistance detection in Klebsiella pneumoniae. (Pubmed Central) - Sep 14, 2024
Incorporating this insight into an AI-CDSS could transform clinical workflows, giving healthcare professionals immediate, crucial insights for shaping treatment plans. This approach promises to be a template for future anti-resistance strategies, emphasizing the vital importance of advanced diagnostics in enhancing public health outcomes.
- | Journal: Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): a new epidemiologic scenario. (Pubmed Central) - Sep 12, 2024
M-CPE is an emerging threat in our hospital. Co-production of different carbapenemases, including metallo-?-lactamases, limits therapeutic options and depicts the need to reinforce infection control measures.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. (Pubmed Central) - Sep 12, 2024
This could potentially lead to effective intervention(s) overlooked by conventional susceptibility testing method. This case highlights the importance of site-specific drug exposures on determining treatment outcome.
- || imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil. (Pubmed Central) - Sep 12, 2024
This study demonstrated that, although high susceptibility rates to the BLBLI were found, KPC-2 isolates can also demonstrate resistance due to porin mutations. Additionally, NDM-1 isolates can demonstrate susceptibility in vitro to the BLBLI.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
Preclinical, Journal, Gram negative: In vitro activity of ceftolozane/tazobactam against Gram-negative bacilli isolated from pediatric patients: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2021, China. (Pubmed Central) - Sep 12, 2024
Additionally, NDM-1 isolates can demonstrate susceptibility in vitro to the BLBLI. GNBs collected from paediatric patients in China showed a high susceptibility to C/T making this drug combination an effective choice for treating the paediatric population, especially those infected with P. aeruginosa.
- | colistin sulphate / Generic mfg.
Journal: Investigation of Rapid Emergence of Colistin Resistance in a Newborn Infected with KPC2-Producing Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae. (Pubmed Central) - Sep 12, 2024
GNBs collected from paediatric patients in China showed a high susceptibility to C/T making this drug combination an effective choice for treating the paediatric population, especially those infected with P. aeruginosa. This study characterizes colistin resistance of the ST11 clone hv-CRKp during colistin treatment and its rapid evolution within the host.
- | Fetroja (cefiderocol) / Shionogi
Preclinical, Journal, Gram negative: In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance. (Pubmed Central) - Sep 12, 2024
This study characterizes colistin resistance of the ST11 clone hv-CRKp during colistin treatment and its rapid evolution within the host. This is the first large-scale study to systematically demonstrate the efficacy of CFDC against IMP-type carbapenemase-producing strains with known genomic backgrounds.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Genome analysis of an extensively drug resistant Pseudomonas aeruginosa ST1791 from a patient in China hospitalized for severe pneumonia. (Pubmed Central) - Sep 12, 2024
This is the first large-scale study to systematically demonstrate the efficacy of CFDC against IMP-type carbapenemase-producing strains with known genomic backgrounds. These findings enhance our understanding of the resistance and pathogenicity of the ST1971 P. aeruginosa strain that is unique in China and provide a broader perspective on the global epidemiological landscape, suggesting the emergence of P. aeruginosa ST1971, which requires control measures to limit its dissemination.
- | Exblifep (cefepime/enmetazobactam) / Allecra, enmetazobactam (AAI101) / Allecra
Journal: Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates. (Pubmed Central) - Sep 12, 2024
Cefepime/enmetazobactam was highly active against Enterobacterales isolates, especially those resistant to third-generation cephalosporins. These data suggest that cefepime/enmetazobactam could be used as a carbapenem-sparing agent to replace piperacillin/tazobactam.
- DIAGNOSTIC AND THERAPEUTIC DIAGNOSTIC DILEMMAS IN THE MANAGEMENT OF GRANULOMATOUS DISEASE IN AN IMMUNOCOMPROMISED PATIENT (Convention Center Exhibit Hall: Rapid Fire Area 2B) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6689;
In conclusion, non tuberculous mycobacterial (NTM) infections need high clinical suspicion for diagnosis. Immunodeficiency should be considered at every NTM infection, and as such a multidisciplinary approach is mandatory to better assess the diagnostic and therapeutic approach.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021. (Pubmed Central) - Sep 10, 2024
No mechanism was identified that is thought to support resistance to these agents in numerous isolates. This may be due in part to the fact that whole genome sequencing (WGS) cannot directly measure gene expression of chromosomal resistance mechanisms.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal, Combination therapy: In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing Enterobacterales. (Pubmed Central) - Sep 9, 2024
Dual-carbapenemase-producing Enterobacterales posed a significant threat to clinical anti-infection treatment. However, the combination of ATM with innovative ?-lactam/?-lactamase inhibitor compounds had proven to be an effective treatment option.
- Fetroja (cefiderocol) / Shionogi, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In vitro antimicrobial activity of the novel antimicrobial peptide OMN-51 against multidrug-resistant Pseudomonas aeruginosa isolated from people with cystic fibrosis () - Sep 4, 2024 - Abstract #NACFC2024NACFC_853;
OMN-51 is a beta-hairpin antimicrobial peptide derived from the innate immune system of Capitella teleta (a marine polychaeta) that selectively disrupts the bacterial membrane, exerting a bactericidal effect on target bacteria. OMN-51 compromises the integrity of the bacterial outer membranes, leading to proton gradient depletion and bacterial cell lysis, followed by rapid bacterial death.
- Emblaveo (aztreonam/avibactam) / Pfizer, AbbVie, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Membrane-remodeling antimicrobials with activity against Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cenocepacia complex () - Sep 4, 2024 - Abstract #NACFC2024NACFC_838;
Activity against Bcc and B. gladioli is particularly interesting given that Burkholderia is intrinsically resistant to many membrane-active antimicrobials. This provides evidence for the differentiation of ACE's membrane-remodeling mechanism, even compared with other agents that target the membrane.
- Emblaveo (aztreonam/avibactam) / Pfizer, AbbVie, imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Activity of ?-lactams and new ?-lactamase inhibitors in multidrug-resistant Burkholderia contaminans () - Sep 4, 2024 - Abstract #NACFC2024NACFC_835;
Although the presence of class D ?-L could contribute, our research suggests that other resistance mechanisms would also be involved. Studies with larger numbers of isolates are needed to validate these results and to establish valid breakpoints for B. contaminans.
- Impact of Urinary Tract Infection due to Carbapenem Resistant Gram Negative Bacteria in Patients with Kidney Transplant (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3365;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Impact of the Introduction of Ceftazidime-Avibactam in the Brazilian Market on Carbapenem and Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae and Pseudomonas aeruginosa: Retrospective Analysis from 2017 to 2023 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3282;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents against Pseudomonas aeruginosa Collected from Patients with Presumed Hospital- and Community-acquired Respiratory Tract Infections as a Part of the ATLAS Global Surveillance Program 2018-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3281;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In Vitro Activity of Ceftazidime-avibactam against Enterobacterales Isolates Producing Multiple ?-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3280;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective Study of Ceftazidime-Avibactam Treatment for Multidrug-Resistant Gram-Negative Bacterial Infections in King Chulalongkorn Memorial Hospital (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3277;
- Clinical Features and Outcomes of KPC and NDM Carbapenemase-Producing Enterobacterales Infection in the Era of Avibactam (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3275;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Ceftazidime-Avibactam for Treating Bacteremic and Non-Bacteremic Carbapenemase-Producing Enterobacterales Infections in Immunocompromised Patients (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3274;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Short-Treatment with Ceftazidime-Avibactam for Carbapenemase-Producing Enterobacterales Bacteremia (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3265;
- Assessment of Beta-lactam Susceptibility Profiles in Pseudomonas aeruginosa: A Comprehensive Analysis at an Academic Medical Center (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3261;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Assessing the novel combinations against Carbapenem resistant Acinetobacter baunmannii (CRAB): ceftazidime-avibactam and ampicillin-sulbactam (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3245;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), cefepime/taniborbactam (cefepime/VNRX-5133) / VenatoRx, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Cefepime-taniborbactam Exhibits Limited Cross-resistance with Ceftazidime-avibactam and Ceftolozane-tazobactam against Carbapenem-nonsusceptible Enterobacterales and Multidrug-resistant Pseudomonas aeruginosa from the United States 2018-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3242;
- imipenem/relebactam / Merck (MSD)
Partnering Imipenem/Relebactam (I/R) with Fosfomycin (FOS): Restoring Susceptibility Against Multi-Drug-Resistant Pseudomonas aeruginosa (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3239;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam and Comparators Against Clinical MDR and DTR non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa Stratified by Patient Age and Hospital Ward: SMART United States 2020-2022 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3237;
- Fetroja (cefiderocol) / Shionogi
Evaluation of Phenotypic Cross-Resistance between Cefiderocol and ?-lactam/?-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US Medical Centers (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3236;
- Fetroja (cefiderocol) / Shionogi, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Two against One: Ceftazidime-Avibactam plus Aztreonam vs Cefiderocol in the Treatment of Metallo-Beta-Lactamase-Producing Bacterial Infections (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3232;
- Cedax (ceftibuten dihydrate) / Currax
In Vitro Activity of Ceftibuten-Avibactam and Comparator Agents Against Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2022 by Region (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3231;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical Characteristics and Factors Associated with Acquisition of Gram-Negative Bacteria during Ceftazidime-avibactam Therapy (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3229;
- Treatment Choices for Carbapenem-Resistant Enterobacterales: An Emerging Infections Network Survey (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3226;
- Fetroja (cefiderocol) / Shionogi
In vitro Activity of Cefiderocol and Comparator Agents Against Global Enterobacterales Isolates From Hospitalized Patients with Pneumonia Collected as Part of the SENTRY Surveillance Program (2020-2022) (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2958;
- Acquired Carbapenemase-Producing Gram-Negative Organisms (CPOs) Across the Pond: Surveillance of Antibiotic Resistance in CPOs in England from 2020-2023 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2925;
- Occurrence of b-lactamases among Enterobacterales isolates from United States Hospitals in a 10-year period: Report from the International Network for Optimal Resistance Monitoring (INFORM) Program (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2922;
- Fetroja (cefiderocol) / Shionogi
Activity of Cefiderocol against Carbapenem Non-susceptible Enterobacterales, Including Molecularly Characterized Multidrug-resistant Clinical Isolates, Causing Infections in United States Hospitals (2020 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2914;
- HAISeq: Monitoring Emerging and Novel Gram-Negative Antimicrobial Threats from Healthcare Settings in the United States with Publicly Available NCBI BioProject Data (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2883;
- Emblaveo (aztreonam/avibactam) / Pfizer, AbbVie
Optimizing the synergy between Aztreonam & Avibactam for NDM plus OXA48 producing Carbapenem resistant Klebsiella pneumoniae infections: an innovative infusion method. (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2831;
- Emblaveo (aztreonam/avibactam) / Pfizer, AbbVie
Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Aztreonam-Avibactam Dosing Regimens (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2812;
- Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Unlocking Potentials: The Impact of Meropenem, Meropenem-vaborbactam, and Ceftazidime-avibactam in Combatting Carbapenem-Resistant Enterobacter cloacae in Epithelial Lining Fluid and Serum (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2810;
- Invasive Infections by Carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa in Children. (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2698;
- The role of Carbapenemase gene detection and synergy testing in invasive infections caused by Carbapenem resistant Enterobacterales in the pediatric population at a quaternary hospital in South India (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2675;
- Cedax (ceftibuten dihydrate) / Currax
In Vitro Potency of Ceftibuten-Avibactam (CTB-AVI) and Comparators against Extended-Spectrum Beta-Lactamase (ESBL)-like Enterobacterales from Outpatient Centers and Nursing Homes in the United States (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2630;